Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 9, 2007, Pages 1069-1077

  Winter, J W ^a,e   Gaffney, D ^b   Shapiro, D ^a   Spooner, R J ^a   Marinaki, A M ^c   Sanderson, J D ^d   Mills, P R ^a  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^b NHS Greater Glasgow and Clyde Clinical Biochemistry Service   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; THIOPURINE METHYLTRANSFERASE 2; THIOPURINE METHYLTRANSFERASE 3 A; THIOPURINE METHYLTRANSFERASE 3 C; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BONE MARROW SUPPRESSION; CONTROLLED STUDY; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME DEFICIENCY; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENOTYPE; HETEROZYGOSITY; HUMAN; LEUKOPENIA; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PREDICTION; PRIORITY JOURNAL; SCREENING TEST; SEQUENTIAL ANALYSIS; SIDE EFFECT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; CLINICAL ENZYME TESTS; COST-BENEFIT ANALYSIS; FEMALE; GASTROINTESTINAL AGENTS; GENETIC TECHNIQUES; GENOTYPE; HUMANS; INFLAMMATORY BOWEL DISEASES; LYMPHOPENIA; MALE; MASS SPECTROMETRY; METHYLTRANSFERASES; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 34247159530     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03301.x     Document Type: Article

References (45)

1. Pearson DC, May GR, Fick G, Sutherland AR. Azathioprine for maintenance of remission in Crohn's disease. The Cochrane Library 2004; Issue 3.
2. Sandborn WSL, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease (Cochrane Review). The Cochrane Library 2004; Issue 3.
3. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-9.
4. George J, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996; 91: 1711-4.
5. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990; 85: 717-22.
6. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2004; 13: 563-7.
7. Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 1743-50.
8. Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002; 12: 429-36.
9. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 1081-5.
10. Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 215-9.
11. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 641-9.
12. Zelinkova Z, Derijks LJ, Stokkers PC, et al. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol 2006; 4: 44-9.
13. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-62.
14. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 608-14.
15. Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004; 14: 407-17.
16. Sasaki T, Goto E, Konno Y, Hiratsuka M, Mizugaki M. Three novel single nucleotide polymorphisms of the human thiopurine s-methyltransferase gene in Japanese individuals. Drug Metab Pharmacokinet 2006; 21: 332-6.
17. Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999; 9: 37-42.
18. McLeod HL, Pritchard SC, Githang'a J, et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 1999; 9: 773-6.
19. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30.
20. Winter J, Walker A, Shapiro D, Gaffney D, Spooner RJ, Mills PR. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20: 593-9.
21. Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 2005; 100: 2239-47.
22. Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002; 29: 2507-12.
23. Oh KT, Anis AH, Bae SC. Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology (Oxford) 2004; 43: 156-63.
24. Tavadia SM, Mydlarski PR, Reis MD, et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000; 42: 628-32.
25. Schwab M, Schaeffeler E, Marx C, Zanger U, Aulitzky W, Eichelbaum M. Shortcoming in the diagnosis of TPMT deficiency in a patient with Crohn's disease using phenotyping only. Gastroenterology 2001; 121: 498-9.
26. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics 2002; 3: 89-98.
27. Chang JG, Lee LS, Chen CM, et al. Molecular analysis of thiopurine S-methyltransferase alleles in South-east Asian populations. Pharmacogenetics 2002; 12: 191-5.
28. Breen DP, Marinaki AM, Arenas M, Hayes PC. Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transpl 2005; 11: 826-33.
29. Marinaki AM, Ansari A, Duley JA, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004; 14: 181-7.
30. Kaskas BA, Louis E, Hindorf U, et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003; 52: 140-2.
31. Langley PG, Underhill J, Tredger JM, Norris S, McFarlane IG. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol 2002; 37: 441-7.
32. Kader HA, Wenner WJ Jr, Telega GW, Maller ES, Baldassano RN. Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. J Clin Gastroenterol 2000; 30: 409-13.
33. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 395-400.
34. Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129: 716-718.
35. Gisbert JP, Nino P, Rodrigo L, Cara C, Guijarro LG. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J Gastroenterol 2006; 101: 2769-76.
36. Campbell S, Kingstone K, Ghosh S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. Aliment Pharmacol Ther 2002; 16: 389-98.
37. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005; 20: 1149-57.
38. Arenas M, Simpson G, Lewis CM, et al. Genetic variation in the MTHFR gene influences thiopurine methyltransferase activity. Clin Chem 2005; 51: 2371-4.
39. Schaeffeler E, Stanulla M, Greil J, et al. A novel TPMT missense mutation associated with TPMT deficiency in a 5-year-old boy with ALL. Leukemia 2003; 17: 1422-4.
40. Arenas M, Duley JA, Ansari A, et al. Genetic determinants of the pre- and post-azathioprine therapy thiopurine methyltransferase activity phenotype. Nucleosides Nucleotides & Nucleic Acids 2004; 23: 1403-1405.
41. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995; 39: 456-9.
42. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49: 665-70.
43. Gilissen LP, Bierau J, Derijks LJ, et al. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment Pharmacol Ther 2005; 22: 605-11.
44. Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 2002; 16: 79-85.
45. Lewis LD, Benin A, Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 1997; 62: 464-75.